IP Library › Granted Patent US 10,004,726
Granted Patent B2
US 10,004,726 · App. 15/072,530 · Granted Jun 26, 2018

Polymorphs of cocrystals of P-coumaric acid:nicotinamide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,726
App. No.
15/072,530
Granted
Jun 26, 2018
Kind
B2
Abstract

Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.

Claims (12)

1. Form III of a 1:1 cocrystal of p-coumaric acid and nicotinamide.

2. The cocrystal of claim 1 , wherein the x-ray powder diffraction pattern of the cocrystal has a peak at about 25.8° 2θ.

3. The cocrystal of claim 1 having a melting onset temperature of about 160° C.

4. The cocrystal of claim 1 , wherein the x-ray powder diffraction pattern of the cocrystal has a single peak between about 15.4° 2θ and about 16.0° 2θ.

5. The cocrystal of claim 2 having a melting onset temperature of about 160° C.

6. The cocrystal of claim 4 having a melting onset temperature of about 160° C.

7. The cocrystal of claim 3 , wherein the melting onset temperature is determined by differential scanning calorimetry.

8. The cocrystal of claim 5 , wherein the melting onset temperature is determined by differential scanning calorimetry.

9. The cocrystal of claim 6 , wherein the melting onset temperature is determined by differential scanning calorimetry.

10. A pharmaceutical composition comprising the cocrystal of claim 1 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10 , wherein the x-ray powder diffraction pattern of the composition exhibits a peak at about 25.8° 2θ.

12. The pharmaceutical composition of claim 10 , wherein the x-ray powder diffraction pattern of the cocrystal has a peak at about 25.8° 2θ.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2025
From: CURIA INDIANA, LLC
To: CURIA GLOBAL, INC.
Reel/Frame 073047/0677 →
CHANGE OF NAME Recorded May 20, 2025
From: AMRI SSCI, LLC
To: CURIA INDIANA, LLC
Reel/Frame 071298/0518 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON SEPTEMBER 1, 2017, AT REEL/FRAME 043746/0621 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0279 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON MARCH 16, 2023, AT REEL/FRAME 063008/0046 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0241 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 063008/0185 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063008/0046 →
SECURITY INTEREST Recorded Sep 6, 2021
From: CURIA GLOBAL, INC. (FKA ALBANY MOLECULAR RESEARCH, INC.); CURIA MASSACHUSETTS, INC. (FKA AMRI BURLINGTON, INC.); CURIA WISCONSIN, INC. (FKA CEDARBURG PHARMACEUTICALS, INC.); CURIA INDIANA, LLC (FKA AMRI SSCI, LLC); CURIA NEW MEXICO, LLC (FKA OSO BIOPHARMACEUTICALS MANUFACTURING, LLC); CURIA IP HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 057423/0665 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
Reel/Frame 054252/0687 →
FIRST LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC-BY ITS SOLE MEMBER: ALO ACQUISITION LLC
To: BARCLAYS BANK, PLC AS COLLATERAL AGENT
Reel/Frame 043746/0621 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING LLC-BY ITS SOLE MEMBER:ALO ACQUISITION LLC
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 043746/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2017
From: BEVILL, MELANIE JANELLE; SCHULTHEISS, NATE
To: AMRI SSCI, LLC
Reel/Frame 041372/0432 →